The Observation: Two Quotes, One Sequence, No Way to Tell Them Apart
Penetratin Supplier Neuropeptide S The failure pattern is easy to recognize once you know what to look for. A sequence string is submitted twice, verbatim. Two quote documents come back. The totals differ by a multiple. Neither document states the basis of its price: not the quantity basis, not the purity method, not which analyses are included, not the salt form, not the rework terms.
Hypothetical example (illustrative only, all prices to be quoted). A 24-residue sequence with a single disulfide bond is requested at 5 mg and ≥95% purity. Supplier A returns a total of “to be quoted” against a specification sheet listing HPLC and MS only. Supplier B returns a total of “to be quoted” against a sheet that also lists nitrogen analysis, a TFA-exchange step, and a stated resynthesis policy for failed lots. The two totals are not comparable, and no arithmetic will make them comparable, because the deliverables differ.
What is observed is the gap. What caused it is not yet known. Treating the lower number as the better price is the error that starts the whole failure chain, because it commits the project to a scope that may not deliver the material the assay needs.
There is one documented anchor worth noting. GenScript’s own peptide service comparison lists distinct tiers — a fast-turnaround service limited to 4–25 residues at ≥95% purity and 4 mg, and a regular service spanning up to <200 residues, crude to ≥98% purity, mg to kg — with different included modifications and different add-on analyses. A quote’s tier is therefore itself a specification variable, and two quotes can differ simply because one was built on a tier the other was not.
Hypothesis: What Actually Moves a Custom Peptide Synthesis Price
A price gap has to come from somewhere. The candidate explanations below are hypotheses to be tested against the documents, not conclusions about any particular supplier. Each is tied to a cost mechanism rather than a figure.
Illustrative mass balance only: a published worked example (98.40% HPLC purity, 5.80% water, 11.20% TFA counterion, 0.40% residual solvents) recalculated as shares of one gram of gross powder. This is a hypothetical example based on a published calculation, not a GenScript specification, not a quote, and not a typical value for any particular sequence. Purity and net peptide content are separate measurements on separate denominators.
The drivers, roughly in the order a quote tends to vary them: sequence length and difficult segments; target quantity; purity grade and the preparative chromatography burden it implies; net peptide content versus gross weight; modifications, salt form and optional analytics; and the QC and delivery scope bundled into the total. The three that most often explain a large gap are treated separately below.
Sequence length and difficult fragments
Residue count alone under-describes synthesis difficulty. Each residue is another coupling and deprotection cycle, and yield generally falls as the chain grows, but the sequence composition matters as much as the count. Hydrophobic stretches can promote on-resin aggregation; aggregation-prone regions can suppress coupling efficiency; long chains compound both. A published cost-driver guide describes hydrophobic-rich sequences as costing more because they aggregate during synthesis and may require double couplings and special solvents — an orientation statement from that publisher, not a quotation.
GenScript’s PepPower platform page states synthesis is feasible up to 200 amino acids and lists a successful-synthesis rate above 95% for its platform, while the service page notes that sequences longer than 100 residues are “extremely difficult to synthesize” and are evaluated case by case. That case-by-case language is the operative point: a quote that reflects a manual difficulty review is not evidence of overcharging, and a quote that ignores difficulty is not evidence of a bargain. What a buyer should look for in the sequence is anything that would plausibly trigger that review — long hydrophobic runs, multiple disulfides, dense basic regions, non-natural residues.
Purity grade versus net peptide content
These are two different measurements with two different denominators, and conflating them is the most common specification error in peptide procurement.
HPLC purity is a percentage of total detected peak area: how much of the UV-absorbing material that eluted is the target sequence. Net peptide content is a percentage of the weighed mass: how much of the powder in the vial is peptide at all. Water, counterion and residual solvent do not appear in a chromatogram at 214 nm, so a ≥95% HPLC figure says nothing about how much of the powder is peptide. A net peptide content explainer sets out the distinction and notes that for peptides with several basic residues the counterion alone can account for 10–30% of total weight, and occasionally more.
GenScript’s service table lists nitrogen analysis and amino-acid analysis as available content methods. If one quote prices 5 mg of gross powder and the other prices 5 mg of peptide content, the two are not the same order — and the difference in usable material can be substantial.
Modifications, salt form and analytical packages
Every addition to the molecule is additional scope. N-terminal acetylation and C-terminal amidation, fluorescent or biotin labels, carrier conjugation, disulfide formation and head-to-tail cyclisation each add reagents, steps and purification burden. GenScript’s comparison table lists amidation and acetylation as free on one tier, with biotin, FAM and FITC labels, carrier proteins and a single disulfide bond as time-adding items, and the regular service as offering 300+ modifications.
Salt form is a separate line item that catches buyers out. Peptides are typically isolated as TFA salts, and exchanging to acetate or hydrochloride adds a processing step; the syn-peptide guide estimates such an exchange at roughly 15–25% of base price — again that publisher’s orientation figure, not a quote. GenScript’s TFA review page discusses why residual TFA matters for downstream assays.
Optional analytics — content analysis, water by Karl Fischer, counterion by ion chromatography, endotoxin testing — each add scope. A quote that omits them is not comparable to one that includes them; it is a quote for less work.
Verification: Build a Like-for-Like Comparison Before You Argue About Price
Before arguing about price, normalize both quotes onto one specification sheet. The comparison only holds when the following are identical on both sides: sequence version (including any residue changes since the first submission), quantity basis (gross powder versus net peptide), purity percentage and its stated method, salt form, modification list line by line, analytical deliverables, and rework and resynthesis terms.
Anything not confirmed in writing on the quote is an open question, not an assumption. GenScript’s published QC and service pages are the place to confirm which items are standard for a given tier and which are add-ons — but confirm the specific quote, not the general page.
RFQ fields to fill before resubmitting:
-
Sequence, written N- to C-terminus, with a version number and date
-
N- and C-terminus stated explicitly (free amine, free acid, acetylated, amidated)
-
Modification site and chemistry for Casomorphin every non-standard residue or label
-
Disulfide positions, if any
-
Target quantity, and whether it is gross powder or net peptide
-
Purity percentage and its basis (HPLC method, wavelength, integration criteria)
-
Salt form, and residual TFA limit if the assay is sensitive to it
-
Required analytical data: HPLC, MS, content analysis, water, counterion, endotoxin
-
Aliquot configuration and delivery form
-
Required delivery date, and whether expedited turnaround is requested
-
Rework, resynthesis and acceptance terms Peptide Custom Synthesis
A quote that answers all twelve fields can be compared with another that answers all twelve. A quote that answers six cannot.
The Diagnostic Table: Symptom, Possible Cause, Verification Evidence, Next Step
The table below maps an observed discrepancy to a candidate explanation, the artifact that would confirm or rule it out, and the corrective step. A matching symptom does not establish causation — several rows can apply at once, and the table narrows the question rather than settling it.
|
Symptom |
Possible cause |
Verification evidence |
Next step |
|---|---|---|---|
|
Large total gap, identical sequence string |
Different service tier, or difficulty review applied to one quote only |
Quote line items naming the tier; written note on sequence difficulty |
Ask both suppliers to state the tier and any difficulty adjustment in writing |
|
Cheaper quote silent on content analysis |
Priced on gross powder, not net peptide |
Quote deliverable list; CoA field for peptide content |
Request a re-quote on a stated net peptide basis |
|
Purity figure with no method or basis |
Different HPLC method, wavelength or integration criteria |
Method reference on the quote or CoA |
Require the method to be named before comparing percentages |
|
Modification in one quote, absent from the other |
Scope difference, not price difference |
Modification list, line by Penetratin Factory line, on both documents |
Add the missing item to the lower-scope quote and re-compare |
|
Salt form unspecified |
One quote assumes default TFA salt; the other includes exchange |
Written salt-form statement; residual TFA specification |
Specify salt form and TFA limit in the RFQ |
|
Delivery date differs without explanation |
Expedited service, or a longer queue for a difficult sequence |
Written turnaround commitment and its stated start point |
Confirm whether the date is guaranteed and what compensation applies |
|
Rework clause absent or vague |
Resynthesis risk carried by the buyer, not priced in |
Written acceptance and resynthesis terms |
Require the clause in writing before signing |
A note on the purity row: a stated percentage without a stated method is not a comparable number, because different gradients and wavelengths can integrate differently. The same discipline applies to content figures — a content value is only comparable to another obtained by the same method and on the same reporting basis.
Correction: Rewrite the Specification, Not Just the Price
The correction is a rewritten RFQ, not a negotiated number. Returning to the hypothetical 24-residue, single-disulfide example: the corrected request states the sequence with a version number, specifies 5 mg net peptide rather than 5 mg powder, names ≥95% purity by reversed-phase HPLC with the method to be stated on the CoA, requires HPLC and MS as standard deliverables plus nitrogen analysis for content, specifies the salt form and any residual TFA limit, lists the disulfide as a required modification, and asks each supplier to state its resynthesis and acceptance terms in writing. Both totals remain “to be quoted.” The comparison is now meaningful because the scope is identical.
Acceptance checklist before signing:
-
Purity basis stated, with method
-
Content basis stated (net peptide, and by which method) Of Peptides Manufacturer
-
Salt form stated
-
Modification list matched line by line against the RFQ
-
Analytical deliverables enumerated
-
Rework and acceptance terms in writing
-
Sequence version recorded on the quote
Rework risk deserves separate attention because it does not appear in the total. A quote that omits content analysis, or leaves resynthesis terms unstated, shifts a cost to the buyer that the higher quote may have priced in. For a difficult sequence, the expected cost of a failed lot — in resynthesis, in lost time, in a delayed assay — can exceed the visible gap between the two quotes. That is a judgment about risk allocation, not a claim that any specific sequence will fail.
Where MOL Changes fits: as a peptide research and development organization offering custom synthesis, modification services and analytical support, MOL Changes can quote against a fully specified RFQ of the kind above. Readers with a defined project specification can submit it for a scope-based quotation. Whether a given sequence, quantity or modification set is feasible is a question for that quotation, not something this article asserts.
Disclosure: MOL Changes is a commercial peptide supplier and has a business interest in the quality standards discussed here.
Sources and Scope Notes
Sources are listed with what each supports and what it does not. No GenScript custom-sequence price was found in the retrieved material.
-
GenScript, Custom Peptide Synthesis service comparison — supports the existence of distinct service tiers with different length ranges (4–25 aa versus <200 aa), purity ranges (≥95% versus crude to ≥98%), quantities (4 mg versus mg to kg), included modifications, and available content-analysis methods (nitrogen, amino-acid analysis). Does not publish prices for custom sequences. The page also carries the statement that sequences longer than 100 residues are extremely difficult and evaluated case by case.
-
GenScript, PepPower™ Peptide Synthesis Platform — supports the stated synthesis ceiling of up to 200 amino acids and the platform’s own reported successful-synthesis rate. The rate is the supplier’s own figure and is not treated here as a guarantee for any specific sequence.
-
GenScript, cGMP Peptide Synthesis quality-attribute table — illustrates which attributes a specification can name (appearance, molecular weight, identification, purity, related substances, ion content, water content, residual solvents, elemental impurities, microbial limit, endotoxin, sterility) and the method references behind them. These are GMP drug-substance criteria; they are not implied to apply to research-grade orders. The page states that pricing and quantity ranges are available on request.
-
Patriot Labs, What Is Net Peptide Content — supports the purity-versus-content distinction, the counterion contribution to mass, and the point that content and purity are never simply substituted for one another.
-
SynPeptide, How Much Does Peptide Synthesis Cost? A 2026 Pricing Guide, dated 2026-07-05 — supports the general relationship between length, purity, scale, modification scope and cost, and the observation that sequences beyond roughly thirty residues usually move to custom quotation. Its price ranges and percentage estimates are that publisher’s orientation figures and are not reproduced here as quotes.
Gaps and conditions. No GenScript custom-sequence price, turnaround guarantee or success-rate figure is treated here as binding. No supplier ranking is implied. The troubleshooting logic holds when both quotes can be normalized onto the same specification fields; it cannot resolve a gap whose cause the supplier has not stated in writing. The actual cause of any specific quote difference can only be confirmed by the supplier, in writing, against the corrected RFQ.
Frequently Asked Questions
Why can two quotes for the same sequence differ so much?
Most often because they price different scopes. The usual suspects are service tier, quantity basis (gross powder versus net peptide), purity method, salt form, modification list and analytical deliverables. Compare the specification fields before comparing the totals.
How do I tell whether a quote is priced on gross mass or net peptide content?
Look for an explicit statement on the quote or in the CoA field list. If neither document names a content method — nitrogen analysis, amino-acid analysis or mass balance — the basis is unstated, and the usable peptide per vial cannot be calculated from the quote alone. Ask for the basis in writing.
Which RFQ fields are mandatory for a like-for-like comparison?
At minimum: sequence with N- and C-terminus, modification sites and chemistry, disulfide positions, quantity with its basis, purity percentage with its method, salt form, required analytical data, aliquot and delivery form, timeline, and rework terms. A quote missing any of these is not yet comparable.
What should be confirmed in writing before accepting a quote?
Purity basis and method, content basis, salt form and residual TFA limit if relevant, the full list of included QC deliverables, and the rework and acceptance terms. Anything confirmed only verbally remains an open question.
Publisher disclosure: MOL Changes supplies peptide services and has a commercial interest in this topic. Service ranges and capability statements are supplier claims; availability and performance for a specific construct require project-specific evidence.
